FTC puts conditions on Eli Lilly's proposed acquisition of Novartis Animal Health

23 December 2014

US pharma major Eli Lilly (NYSE: LLY) has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs in order to settle US Federal Trade Commission charges that its proposed acquisition of Novartis Animal Health from Swiss drugs giant Novartis (NOVN: VX) would likely be anticompetitive.

Earlier this year, Novartis has agreed to divest its Animal Health Division to Lilly for around $5.4 billion (The Pharma Letter April 22). Under the proposed settlement, Eli Lilly will divest its Sentinel product line and associated assets to the French pharmaceutical company, Virbac SA.

Eli Lilly, through its Elanco Animal Health division, and the Novartis Animal Health business unit both develop and market a wide range of animal health products, including medications to treat diseases and conditions affecting pets and livestock.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK